Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Advanced Solid Tumor × talazoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 4 Triple Negative Breast Neoplasms 3 Neuroectodermal Tumors, Primitive, Peripheral 2 Leukemia, Myeloid, Acute 2 Carcinoma, Renal Cell 2 Wilms Tumor 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Recurrence 1 Osteosarcoma 1 Neuroblastoma 1 Neoplasms 1 Kidney Neoplasms 1 Hepatoblastoma 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Solid Tumor 1 Advanced Ovarian Cancer 1

Interventions

Injections 13 toripalimab 9 Carboplatin 5 pembrolizumab 4 atezolizumab 4 Paclitaxel 4 Gemcitabine 4 Oxaliplatin 3 Fluorouracil 3 Cisplatin 3 Bevacizumab 3 trastuzumab deruxtecan 2 tislelizumab 2 niraparib 2 lenvatinib 2 Pemetrexed 2 Leucovorin 2 Albumin-Bound Paclitaxel 2 talazoparib 1 spartalizumab 1 sintilimab 1 penpulimab 1 olaparib 1 nedaplatin 1 mirdametinib 1 enfortumab vedotin 1 conteltinib 1 Nivolumab 1 Magnetic Resonance Spectroscopy 1 Letrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04497116 2025-10-21

TRESR

Repare Therapeutics

Phase 1/2 Completed

276 enrolled 33 charts

Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡